



**Contacts:**

David Waldman or Justyna Gudaszevska

Crescendo Communications Europe

Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)

Tel: (+48 71) 79 11 551

**Milestone Medical Announces Abstract Accepted for Presentation at the 35th Annual Scientific Meeting of the American Pain Society**

**LIVINGSTON, NJ, January 7, 2016 – Milestone Medical (WAR:MMD)** today announced that its abstract previously submitted to the prestigious Journal of Pain has been accepted for presentation and publication. The abstract, entitled, “Real-Time Epidural Space Identification with the CompuFlo® Epidural Instrument is Equivalent to Loss of Resistance Technique Coupled with the Fluoroscopy Confirmation,” will detail the results of the Company’s prospective, open labeled, clinical trial assessing the CompuFlo® technology in correctly identifying the epidural space during an epidural procedure.

The abstract has been accepted for presentation as a poster at the 35th Annual Scientific Meeting of the American Pain Society, May 11-14, 2016 at the Austin Convention Center, Austin, TX. The abstract will be published in a supplemental issue of the Journal of Pain. The Journal of Pain will also publish the abstract in an online searchable database about 6 weeks prior to the annual meeting.

Milestone Medical designed the study, in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space.

Leonard Osser, Chief Executive Officer of Milestone Medical, commented, “We are pleased to announce that our abstract detailing the results of this clinical trial has been accepted for publication in the prestigious Journal of Pain. We look forward to formally presenting the data at the 35th Annual Scientific Meeting of the American Pain Society this spring.”

**About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*